Contract drug services

Contract drug services provider WuXi Biologics announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a slowdown in biotech financing, after seeing a strong recovery in demand in the second half of last year.

FAST NEWS: WuXi Biologics boosts new projects target

The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…
2269.HK

Recent Articles

RELATED ARTICLES

  1. WuXi Biologics
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  2. BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
    2359.HK 603259.SHG
  3. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  4. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  5. Cancer drug maker Genfleet joins Hong Kong IPO influx
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva